CKMed is a specialist medical practice in Rixensart. Private Limited, started on 28 December 2023, 1 establishment.

What is the address of CKMed?

The registered office of CKMed is located at Rue Haute 26, 1330 Rixensart.

Is CKMed still active?

Yes. According to the CBE (1 October 2026) CKMed is active, legal situation “Normale toestand”, started on 28 December 2023.

Is CKMed registered on Peppol?

Yes, CKMed is registered on the Peppol network with ID 0208:1004006022.

What is the enterprise number of CKMed?

The enterprise number of CKMed is BE1004006022.

When was CKMed founded?

CKMed was founded on 28 December 2023.

Who are the directors of CKMed?

According to the 2025 annual accounts, the directors of CKMed are: Charles KNAUF.

Is CKMed a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 December 2023; 2 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CKMed make in 2025?

CKMed posted a profit after taxes of € 111,721 in financial year 2025.

What is the revenue of CKMed?

As a small company, CKMed is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 163,068.

CKMed (Private Limited) - Rixensart - BE1004006022

Dossier CKMed, printed on 1 October 2026 from databakkes.be/en/1004006022/ckmed. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CKMed from Rixensart, company number BE1004006022, closed financial year 2025 with a result of € 111,721 after tax. For that financial year CKMed recorded a gross margin of € 163,068 and equity of € 220,817. Compared with financial year 2024, the result moved from € 138,355 to € 111,721. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 31, 2026.

What it is worth Growing

€ 220,817

▲ 75% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 111,721

▼ 19% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 191,859

▲ 41% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 17,143 paid out

15 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 47,416

▼ 20% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 42,724

▼ 25% vs 2024

€ 14,545 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 1,177

▼ 98% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 9,576

▼ 80% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2024	2025	Change 2024 → 2025
Gross margin	€ 185,647 Gross margin 2024: € 185,647 First fiscal year in the series	€ 163,068 Gross margin 2025: € 163,068 ▼ 12% vs 2024 (€ 185,647) Unfavourable step	▼ 12%
Profit after taxes	€ 138,355 Profit after taxes 2024: € 138,355 First fiscal year in the series	€ 111,721 Profit after taxes 2025: € 111,721 ▼ 19% vs 2024 (€ 138,355) Unfavourable step	▼ 19%
Equity	€ 126,240 Equity 2024: € 126,240 First fiscal year in the series	€ 220,817 Equity 2025: € 220,817 ▲ 75% vs 2024 (€ 126,240) Favourable step	▲ 75%
Total debts	€ 180,646 Total debts 2024: € 180,646 First fiscal year in the series	€ 71,949 Total debts 2025: € 71,949 ▼ 60% vs 2024 (€ 180,646) Favourable step	▼ 60%
Cash	€ 135,743 Cash 2024: € 135,743 First fiscal year in the series	€ 191,859 Cash 2025: € 191,859 ▲ 41% vs 2024 (€ 135,743) Favourable step	▲ 41%
Retained profit	€ 124,240 Retained profit 2024: € 124,240 First fiscal year in the series	€ 218,817 Retained profit 2025: € 218,817 ▲ 76% vs 2024 (€ 124,240) Favourable step	▲ 76%
Dividend	€ 14,115 Dividend 2024: € 14,115 First fiscal year in the series	€ 17,143 Dividend 2025: € 17,143 ▲ 21% vs 2024 (€ 14,115) Unchanged	▲ 21%
Bank debt	€ 56,715 Bank debt 2024: € 56,715 First fiscal year in the series	€ 42,724 Bank debt 2025: € 42,724 ▼ 25% vs 2024 (€ 56,715) Favourable step	▼ 25%
Balance sheet total	€ 306,885 Balance sheet total 2024: € 306,885 First fiscal year in the series	€ 292,767 Balance sheet total 2025: € 292,767 ▼ 5% vs 2024 (€ 306,885) Unchanged	▼ 5%

Key figures of CKMed, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to CKMed?

What happened at CKMed in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 31, 2026 New annual accounts for financial year 2025: profit of € 111,721 (▼ 19% vs 2024). Source: NBB ↗
Dec 28, 2023 New establishment in Rixensart. KBO
2023 Charles KNAUF became a director. NBB
Dec 28, 2023 Start of the company according to the CBE. KBO

In short

From € 138,355 profit in 2024 to € 111,721 profit in 2025.

Paid € 74,594 in corporate taxes since 2024.

Best year ever: 2024, with € 138,355 profit.

Paid out € 31,258 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at CKMed? We notify you, reason included.

Follow CKMed

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Charles KNAUF

CKMed

Behind CKMed is Charles KNAUF.

See the full network in the app

Directors

According to the 2025 annual accounts

Charles KNAUF

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Haute 26

1330 Rixensart

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 1004.006.022
VAT number: BE 1004.006.022
Registered office: Rue Haute 26, 1330 Rixensart
Names & denominations: CKMed
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 28 December 2023
Peppol: Active · Active since 2 Jan 2026
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗